--- title: "U.S. stock market update: ALX Oncology up 11.61%" description: "ALX Oncology rose 11.61%; PepGen rose 126.32%, with a trading volume of USD 618 million; uniQure rose 8.47%, with a trading volume of USD 550 million; AbbVie fell 0.59%, with a trading volume of USD 4" type: "news" locale: "en" url: "https://longbridge.com/en/news/258926143.md" published_at: "2025-09-25T16:27:41.000Z" --- # U.S. stock market update: ALX Oncology up 11.61% > ALX Oncology rose 11.61%; PepGen rose 126.32%, with a trading volume of USD 618 million; uniQure rose 8.47%, with a trading volume of USD 550 million; AbbVie fell 0.59%, with a trading volume of USD 411 million; Amgen fell 2.45%, with a market capitalization of USD 146.6 billion **U.S. Stock Market Midday Update** **Stocks with High Trading Volume in the Industry** PepGen rose 126.32%, with increased trading volume. Based on recent important news: 1. On September 25, PepGen announced that its experimental drug PGN-EDODM1 showed the ability to improve the cellular processing of genetic instructions in patients with muscle diseases during early trials, leading to a 130% increase in stock price. The drug aims to treat muscle atrophy diseases, and PepGen believes that correcting erroneous RNA splicing can help reverse symptoms. Source: Company announcement. 2. On September 25, PepGen announced a public offering priced at $100 million, issuing 31,250,000 shares at a price of $3.20 per share. This move aims to support its research and clinical trials, driving the stock price up. Source: Company announcement. 3. On September 25, Guggenheim reiterated its buy rating on PepGen and maintained a target price of $6, further boosting the stock price. Source: Analyst report. Market volatility is significant, and industry trends should be monitored. uniQure rose 8.47%, with a trading volume of $550 million. Based on recent important news: 1. On September 25, uniQure announced that its AMT-130 gene therapy showed significant disease progression slowing effects in early to mid-stage trials for Huntington's disease, causing the stock price to soar by about 248%. Data indicates that the therapy has potential breakthrough capabilities, boosting market optimism about the company's prospects. Source: Company announcement. 2. On September 25, uniQure launched a $200 million public offering, including common stock and pre-funded warrants, to support the potential commercialization of AMT-130 in the U.S. This move enhances the company's financial flexibility. Source: Company announcement. 3. On September 25, Stifel and Chardan Capital raised their target prices for uniQure to $65 and $76, respectively, reflecting analysts' confidence in the company's future growth. Source: Analyst report. The outlook for the gene therapy industry is optimistic, with significant capital inflow. AbbVie fell 0.59%, with a trading volume of $411 million. Based on recent key news: 1. On September 25, a U.S. federal judge dismissed AbbVie and Novartis's attempt to challenge Maine's law regulating the use of contract pharmacies under the federal 340B drug discount program. This ruling may negatively impact AbbVie's market performance. 2. On September 23, AbbVie announced that its ibrutinib injection has filed for new indications in China, which may drive its market expansion in China. 3. On September 24, AbbVie announced the acquisition of Capstan, promoting development in the immunology field, which may have a positive impact on its long-term growth. Industry trends are stable, and capital flows are active **Stocks Ranked Among the Top by Market Capitalization in the Industry** Amgen fell 2.45%, with a market capitalization of $146.6 billion. Based on recent important news: 1. On September 24, Citigroup raised Amgen's target price from $310 to $315, maintaining a "Hold" rating. This move indicates an increase in market confidence in Amgen, but failed to significantly boost the stock price. 2. On September 23, market analysis suggested that despite Amgen's non-GAAP earnings per share guidance being raised, the stock price remains under pressure due to political pressures facing the pharmaceutical industry. 3. On September 23, market analysts generally maintained a "Hold" rating on Amgen, believing that five other stocks offer greater investment value, which has had a certain negative impact on Amgen's market performance. The pharmaceutical industry is facing political pressure, leading to stock price volatility ### Related Stocks - [ALXO.US - ALX Oncology](https://longbridge.com/en/quote/ALXO.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | ALX Oncology 在 Evorpacept 治疗 HER2 阳性转移性乳腺癌的二期临床试验中为首位患者给药 | ALX Oncology Holdings Inc. 已经在其 ALX2004 的 I 期临床试验中启动了第三剂量组，该药物是一种针对晚期或转移性 EGFR 表达的实体肿瘤的 EGFR 靶向抗体药物偶联物。该试验目前正在招募多种癌症患者，包 | [Link](https://longbridge.com/en/news/271940383.md) | | ALX Oncology 将在第 44 届摩根大通医疗健康大会上发表演讲 \| ALXO 股票新闻 | ALX Oncology Holdings Inc.（纳斯达克代码：ALXO）将于 2026 年 1 月 15 日太平洋时间中午 12:00 在第 44 届摩根大通医疗健康大会上进行演讲。首席执行官 Jason Lettmann 和首席医学 | [Link](https://longbridge.com/en/news/271960009.md) | | 董事兼 10% 股东 Corey S. Goodman 报告收购 ALX Oncology Holdings Inc.的普通股 | Corey S. Goodman，ALX Oncology Holdings Inc. 的董事及 10% 股东，已报告收购该公司的普通股。完整的文件可通过提供的链接获取。此新闻简报由公共技术生成，仅供信息参考，不应被视为财务、投资或法律建议 | [Link](https://longbridge.com/en/news/274868585.md) | | ALX Oncology 公布乳腺癌 Ib/II 期试验结果 | ALX Oncology 宣布其 CD47 抑制剂 evorpacept 与 Jazz Pharmaceuticals 的 Ziihera 联合治疗 HER2 阳性转移性乳腺癌的 Ib/II 期试验取得了令人鼓舞的结果。试验显示，在九名经过 | [Link](https://longbridge.com/en/news/274508092.md) | | ALX Oncology 报告指出，CD47 生物标志物可以预测晚期 HER2 阳性乳腺癌患者对 Evorpacept 的治疗反应 | ALX Oncology Holdings Inc. 报告了其 CD47 抑制剂 evorpacept 在 1b/2 期临床试验中的新发现，显示 CD47 表达可以预测晚期 HER2 阳性乳腺癌患者对 evorpacept 的反应。该分析与 | [Link](https://longbridge.com/en/news/274315355.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.